Aura Biosciences, Inc.

Listed Company

AURACIK 0001501796NasdaqEmerging GrowthBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-106.20M

Total Assets

$169.43M

Equity

$136.91M

Shares Out

103.39M

Op. Cash Flow

$-84.70M

AURA$6.98−2.31% · past yearDBEQ Basic

Daily closing prices

Business

Aura Biosciences is a clinical-stage biotechnology company developing precision therapies to treat solid tumors while preserving organ function. Its lead candidate bel-sar, a virus-like drug conjugate with a dual mechanism of action, is in late-stage clinical development for early choroidal melanoma, metastases to the choroid, ocular surface cancers, and non-muscle-invasive bladder cancer. The company focuses on ocular and urologic oncology indications where local targeted therapies enable early intervention before metastasis.

Summary from 10-K filed 2026-03-30

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	90	73	65	42	25
General and administrative	22	23	20	18	10
Total operating expenses	113	96	85	60	35
Total operating loss	−113	−96	−85	−60	−35
Interest income, including amortization and accretion income	7	9	9	2	13,000
Other income (expense)	77,000	−120,000	−76,000	−14,000	—
Total other income	7	9	9	2	−1,000
Loss before income taxes	−106	−87	−76	−59	—
Income tax provision, net	−100,000	−100,000	−100,000	0	—
Net loss	−106	−87	−76	−59	−35
Net loss per common share - basic	−1.76	−1.75	−1.93	−1.96	−8.95
Net loss per common share - diluted	−1.76	−1.75	−1.93	−1.96	−8.95
Weighted average common stock outstanding - basic	60	50	40	30	5
Weighted average common stock outstanding - diluted	60	50	40	30	5
Unrealized loss on marketable securities	−179,000	−271,000	611,000	−72,000	—
Currency translation adjustment	−186,000	−5,000	—	—	—
Total other comprehensive loss	−365,000	−276,000	611,000	−72,000	—
Total comprehensive loss	−107	−87	−76	−59	−35

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	60	32	41	122	149
Marketable securities	85	119	185	67	—
Prepaid expenses and other current assets	5	10	6	8	5
Total current assets	150	161	232	197	154
Restricted cash and deposits	768,000	768,000	768,000	768,000	125,000
Right of use assets - operating lease	16	17	19	21	950,000
Other long-term assets	471,000	518,000	509,000	423,000	—
Property and equipment, net	3	3	3	5	5
Total Assets	169	183	255	224	160
Accounts payable	2	2	2	3	2
Short-term operating lease liability	3	3	3	3	615,000
Accrued expenses and other current liabilities	14	9	8	5	4
Total current liabilities	18	15	12	10	7
Long-term operating lease liability	14	16	17	18	360,000
Total Liabilities	33	31	29	28	8
Commitments and Contingencies (Note 12)	—	—	—	—	—
Common stock, $0.00001 par value, 150,000,000 authorized at December 31, 2025 and December 31, 2024, and 63,587,777 and 49,998,279 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	—	—	—	—	—
Additional paid-in capital	617	526	513	407	304
Accumulated deficit	−480	−374	−287	−211	−152
Accumulated other comprehensive income (loss)	−102,000	263,000	539,000	−72,000	—
Total Stockholders' Equity	137	152	226	196	152
Total Liabilities and Stockholders' Equity	169	183	255	224	160

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−106	−87	−76	−59	−35
Depreciation expense	1	1	1	1	800,000
Accretion income on marketable securities	−2	−5	−4	−527,000	—
Other non-cash items	27,000	−5,000	—	—	—
Stock-based compensation expense	14	12	9	6	2
Non-cash lease expense	2	1	2	968,000	—
Prepaid expenses and other assets	4	−4	4	−3	−4
Other long-term assets	47,000	−9,000	−86,000	−423,000	—
Accounts payable	−846,000	482,000	−1	340,000	1
Accrued expenses and other liabilities	4	2	3	234,000	2
Operating lease liabilities	−1	−788,000	−1	−744,000	—
Net cash used in operating activities	−85	−80	−64	−55	−32
Purchases of property and equipment	−447,000	−1	−709,000	−1	−2
Purchases of marketable securities	−84	−59	−234	−120	—
Proceeds from sale of marketable securities	—	−5,000	—	—	—
Maturities of marketable securities	120	129	120	53	—
Net cash provided by investing activities	36	69	−114	−68	−2
Proceeds from exercise of stock options	1	1	1	430,000	349,000
Proceeds from issuance of common stock from follow-on offering, net of issuance costs	47	0	—	87	79
Proceeds from issuance of pre-funded warrants from follow-on offering, net of issuance costs	14	0	—	—	—
Proceeds from issuance of common stock warrants from follow-on offering, net of issuance costs	9	0	—	—	—
Proceeds from issuance of common stock under ATM facility, net of issuance costs	6	0	3	9	—
Proceeds from ESPP purchases	164,000	177,000	128,000	—	—
Net cash provided by financing activities	77	2	97	96	166
Net increase (decrease) in cash, cash equivalents and restricted cash	28	−9	—	—	—
Effect of exchange rate changes on cash and cash equivalents	−186,000	0	—	—	—
Purchases of property and equipment in accounts payable and accrued expenses and other liabilities	91,000	35,000	94,000	180,000	386,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Aura Biosciences, Inc.'s CIK number?

Aura Biosciences, Inc.'s SEC CIK number is 0001501796 (1501796). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Aura Biosciences, Inc.'s SEC filings?

All of Aura Biosciences, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Aura Biosciences, Inc. last report earnings?

Aura Biosciences, Inc. (AURA) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-216743). This is Aura Biosciences, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Aura Biosciences, Inc.'s most recent earnings 8-K?

Aura Biosciences, Inc.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001193125-26-216743. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Aura Biosciences, Inc.'s latest earnings 8-K →
Look up any company's CIK number →